ABL Bio Inc (298380) — Cash Flow-to-Debt Ratio
ABL Bio Inc (298380) has a Cash Flow-to-Debt Ratio of 0.29x as of March 2026, meaning its operating cash flow of ₩32.84 Billion could theoretically repay 0% of its total liabilities (₩114.79 Billion) in one year. Explore ABL Bio Inc (298380) investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
ABL Bio Inc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for ABL Bio Inc across 10 annual periods. Also explore total assets of ABL Bio Inc for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for ABL Bio Inc (2016–2025)
Year-by-year debt coverage analysis for ABL Bio Inc. For market capitalisation and broader financial context, see ABL Bio Inc stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.33x | ₩-41.25 Billion | ₩124.24 Billion | ▲ +69.0% |
| 2024 | -1.07x | ₩-69.40 Billion | ₩64.70 Billion | ▼ -225.5% |
| 2023 | -0.33x | ₩-28.36 Billion | ₩86.07 Billion | ▼ -152.8% |
| 2022 | 0.62x | ₩72.13 Billion | ₩115.67 Billion | ▲ +114.6% |
| 2021 | -4.27x | ₩-40.61 Billion | ₩9.50 Billion | ▲ +16.6% |
| 2020 | -5.12x | ₩-47.29 Billion | ₩9.23 Billion | ▼ -134.0% |
| 2019 | -2.19x | ₩-23.86 Billion | ₩10.89 Billion | ▼ -105.8% |
| 2018 | -1.06x | ₩-12.67 Billion | ₩11.91 Billion | ▼ -1483.8% |
| 2017 | -0.07x | ₩-7.14 Billion | ₩106.32 Billion | ▲ +57.7% |
| 2016 | -0.16x | ₩-3.12 Billion | ₩19.63 Billion | — |